Financials in USD. Standardized financial statements.
A compact view of how Surface Oncology, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Revenue? | $30.00M | $2.69M | $126.16M | $15.36M | $59.42M | $12.83M | $6.63M |
| Revenue Growth? | +1016.5% | -97.9% | +721.4% | -74.1% | +363.3% | +93.4% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $30.00M | $2.69M | $126.16M | $15.36M | $59.42M | $12.83M | $6.63M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $91.87M | $78.70M | $64.58M | $72.73M | $68.57M | $58.82M | $24.64M |
| Operating Income? | -$61.87M | -$76.01M | $61.59M | -$57.37M | -$9.15M | -$45.99M | -$18.00M |
| EBITDA? | -$61.87M | -$76.01M | $61.59M | -$57.37M | -$9.15M | -$45.03M | -$17.67M |
| Income Before Tax | -$63.59M | -$78.48M | $59.34M | -$54.79M | -$6.60M | -$45.38M | -$17.45M |
| Income Tax Expense | $1.72M | $977,000 | $0 | -$1.78M | $0 | $0 | $0 |
| Net Income? | -$65.30M | -$79.46M | $59.34M | -$53.00M | -$6.60M | -$45.38M | -$17.45M |
| EPS? | $-1.17 | $-1.80 | $1.67 | $-1.90 | $-0.33 | $-2.35 | $-0.90 |
| Diluted EPS? | $-1.17 | $-1.80 | $1.57 | $-1.90 | $-0.33 | $-2.35 | $-0.90 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality